| Name | Title | Contact Details |
|---|
Mesa Verde Convalescent Hosp is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
First Choice Healthcare is a Macon, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Charlotte`s Web wasn`t started as a company, it started as a mission to create a world where good health is attainable for all. The Charlotte`s Web extract was something we gave away to people who could benefit from it, a few at first and then many. We labor every day to make this dream a reality and dedicate all our efforts to making the most trustworthy and dependable hemp products. From our seeds, soil, and hands-on approach to farming, to our own FDA registered manufacturing facilities, our rigorous standards for quality and consistency set Charlotte`s Web products apart. That`s why we are the leader in the industry in product quality, safety, and consistency. Our high-quality hemp extract harnesses powerful botanical benefits. Our field is the science of botanics and unlocking their power is our focus. To that end, our mission remains at the core of everything we do: improve lives, naturally.
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.